

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



**ORAGENICS**

**August 14, 2003**  
Date of Report (Date of earliest event reported)

**ORAGENICS, INC.**  
(Exact name of registrant as specified in its charter)

**Florida**  
(State or other jurisdiction  
of incorporation)

**333-100568**  
(Commission  
File Number)

**59-3410522**  
(IRS Employer  
Identification No.)

**12085 Research Drive**  
**Alachua, Florida 32615**  
(Address of principal executive offices including zip code)

**(386) 418-4018**  
Registrant's telephone number, including area code

**None**  
(Former name or former address, if changed since last report.)

---

**ITEM 7. FINANCIAL INFORMATION AND EXHIBITS**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release

**ITEM 9. REGULATION FD DISCLOSURE**

The Company announced that it had filed a patent application with the United States Patent and Trademark Office covering its probiotic based technology. A copy of the press release is filed as an exhibit to this Form 8-K.

**SIGNATURES**

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 14<sup>th</sup> day of August, 2003.

**ORAGENICS, INC.**  
**(Registrant)**

BY: /s/ Mento A. Soponis  
Mento A. Soponis  
President, Principal Executive Officer and a member of the  
Board of Directors.

Exhibit 99.1

Contact: Mento A. "Chuck" Sponis  
Chief Executive Officer  
Oragenics, Inc. (386) 418-4018

**FOR IMMEDIATE RELEASE**

**ORAGENICS FILES FOR U.S. PATENT ON PROBIOTIC-BASED TECHNOLOGY**

***Biotech Company To Use Probiotics To Maintain Oral Health***

**Alachua, FL (August 14, 2003)** - Oragenics, Inc. (TSX-V: ORA.U), today announced that it has filed a patent application with the United States Patent and Trade Mark Office for its probiotic-based technology for use in developing oral care products for the maintenance of dental and periodontal health.

The human mouth normally harbors over 300 species of bacteria, some of which are responsible for tooth decay and gum diseases. A probiotic is a natural bacterium or other microorganism that contributes a healthy benefit by inhibiting the growth of these disease-causing bacteria. The probiotic approach in developing oral care products complements the Company's patented core technology, known as replacement therapy technology, which uses a genetically modified bacterium to prevent tooth decay. The Company's probiotic technology is in early stages of research and development.

Oragenics, Inc. is an emerging biotechnology research and development company that began operations in 1999. Located in Alachua, Florida at the University of Florida's Sid Martin Biotechnology Development Incubator, Oragenics is developing two new healthcare products, which are exclusively licensed from the University of Florida. The more advanced product is an oral rinse for the prevention of tooth decay, which is anticipated to enter clinical trials in 2004. The second product in pre-clinical development is a broad-spectrum antibiotic. For more information about Oragenics, please consult the Company's website at [www.oragenics.com](http://www.oragenics.com).

*The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.*